Compounded Tirzepatide: What It Is and Whether It's Legal in 2026

If you have been offered “tirzepatide” online for a few hundred dollars a month, you are not being offered Mounjaro or Zepbound. You are being offered a compounded preparation — something a pharmacy mixed — and the rules that govern it changed sharply in 2025 and 2026.

This guide explains what compounded tirzepatide actually is, what the law allows today, and what to ask before you fill a prescription. It does not tell you what to take. That conversation belongs with a healthcare provider who knows your history.

What is compounded tirzepatide?

Tirzepatide is the active ingredient in two Eli Lilly medicines: Mounjaro, approved for type 2 diabetes in adults, and Zepbound, approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Same molecule, two brand names, two different approvals [1].

Compounding is the practice of a pharmacist or physician combining, mixing or altering ingredients to make a medicine for a patient [2]. A compounded tirzepatide product is typically a vial of liquid that a pharmacy prepared from bulk tirzepatide powder, often with an added ingredient such as vitamin B12, niacinamide or glycine, and usually supplied as a multi-dose vial with separate syringes rather than a pre-filled pen.

Three things follow from that, and they matter more than anything else on this page:

• It is not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed [3].
• It is not a generic. Generic drugs are FDA-approved and must demonstrate they behave like the brand. Compounded drugs make no such showing. Mounjaro and Zepbound remain the only FDA-approved tirzepatide products [4].
• It is not automatically illegal either. Compounding is a long-established, lawful practice — within limits. Those limits are where the 2026 story lives.

Why was compounded tirzepatide everywhere in 2023 and 2024?

Because of a shortage, and nothing else.

Federal law generally bars pharmacies and outsourcing facilities from compounding drugs that are “essentially a copy” of a commercially available or approved product. That restriction is relaxed while the drug sits on FDA’s drug shortage list [5].

FDA added Mounjaro to the shortage list in December 2022 and Zepbound in April 2024 [6]. For roughly two years, that listing is what made large-scale compounded tirzepatide lawful. It had nothing to do with any finding that compounded versions were good, safe or equivalent. It was a supply mechanism.

Prices during that window made the appeal obvious. Compounded tirzepatide sold for as little as $99 a month at a time when Zepbound’s sticker price ran above $1,086 [7].

What changed, and exactly when?

The wind-down ran on a specific set of dates. Any article that gives you a vague “2025” is skipping the part that determines whether a product you are being sold today is lawful.

Date	What happened
December 2022	FDA adds Mounjaro to the drug shortage list
April 2024	FDA adds Zepbound to the shortage list
October 2, 2024	FDA determines the tirzepatide injection shortage is resolved
October 22, 2024	Decision remanded to FDA for re-evaluation under litigation
December 19, 2024	FDA reaffirms the shortage is resolved by Declaratory Order
February 18, 2025	End of enforcement discretion for 503A pharmacies
March 19, 2025	End of enforcement discretion for 503B outsourcing facilities

Source for the full sequence: FDA’s own compounder policy page [6].

FDA gave the longer window to outsourcing facilities because of their manufacturing obligations and longer production lead times. Pharmacies could sell already-made stock until it ran out or expired, which is part of why compounded product kept appearing well after the deadlines.

Tirzepatide came off the shortage list roughly two months before semaglutide, so the tirzepatide market began shrinking first. If you have read that “compounded GLP-1s ended in 2025,” that is the semaglutide timeline. Tirzepatide’s clock started in 2024.

Did the compounders fight it? What happened?

Yes, and they lost at every level.

The Outsourcing Facilities Association and a compounder trading as FarmaKeio sued FDA in the Northern District of Texas, arguing the agency should have used formal notice-and-comment rulemaking and that its shortage determination was arbitrary and capricious. Eli Lilly intervened in January 2025 to defend FDA’s decision [8].

The district court denied a preliminary injunction on March 5, 2025 and ruled for FDA on the merits on May 7, 2025 [9]. On August 27, 2026, a Fifth Circuit panel affirmed in an unpublished opinion, No. 25-10600. The court held that any failure to use notice-and-comment rulemaking was harmless because the compounders had actual notice and repeated chances to submit information, and that FDA’s determination was not arbitrary or capricious [10]. A companion opinion decided the semaglutide appeal the same day.

The panel’s reasoning on evidence is worth knowing: FDA credited Eli Lilly’s supply and demand data over wholesaler screenshots, patient surveys and reports collected through a telehealth company’s own web form, and the court found that reasonable [10].

The practical meaning is simple. The shortage route back to mass-compounded tirzepatide is closed, unless tirzepatide returns to the shortage list, which FDA has given no indication of doing.

So what is still legal?

One narrow pathway remains, and one broader one is under threat.

Section 503A patient-specific compounding is still available. A state-licensed pharmacist or physician may compound tirzepatide for an individually identified patient against a valid prescription when the prescriber documents that the compounded product produces a clinically significant difference for that patient compared with the FDA-approved product [5]. The classic examples are a documented allergy to an inactive ingredient in the commercial product, or a strength that is not commercially available.

What does not qualify: cost, convenience, supply preference, wanting a non-standard dose for its own sake, or a prescriber’s general preference. Regulators have been explicit that “cheaper” is not a clinical difference.

Section 503B bulk compounding is essentially shut. An outsourcing facility may only compound from a bulk drug substance if that substance appears on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Tirzepatide is on neither [6]. FDA made this concrete in an April 7, 2026 warning letter to a Pennsylvania outsourcing facility, stating flatly that its compounded tirzepatide was not eligible for the 503B exemptions for exactly that reason [11].

And FDA has proposed to close that door permanently. On April 30, 2026 the agency announced it was proposing not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, finding no clinical need [12]. The comment period, extended once, closed July 30, 2026 [13]. As of September 14, 2026 no final determination had published. If finalized, the exclusion would foreclose the 503B route even if tirzepatide ever returned to shortage.

What about the “personalized” versions with B12 in them?

This is the workaround that kept the market alive, and it is the one regulators are looking at hardest.

After the shortage ended, many sellers added another ingredient — most often a vitamin B12 analog, sometimes niacinamide, levocarnitine or glycine — and described the result as a personalized formulation rather than a copy. FDA’s April 1, 2026 guidance to compounders addresses this directly: adding an ingredient does not automatically mean a product is no longer essentially a copy [6].

How common is it? A University of Colorado Anschutz secret-shopper study published in JAMA Health Forum on July 17, 2026 called 75 confirmed weight-loss clinics and medspas in West Virginia and Oklahoma. It found 86.7 percent still offering compounded tirzepatide after the shortage ended, and 58.7 percent confirming their GLP-1 was compounded with an additive, B vitamins in 56.0 percent of cases [14].

The study’s lead author put the tension plainly: adding a B vitamin and claiming it improves energy or reduces nausea is arguably meeting a specific patient need, but there is a gray area in which a lot of illegitimate prescribing happens under the same banner [15].

There is also a safety wrinkle. In March 2026 Eli Lilly published testing results reporting a previously unidentified impurity formed by a chemical reaction between tirzepatide and B12, at levels up to 10 percent of total protein content in the samples it tested, and called for a recall [16]. The compounding industry’s trade group disputed the claims. No one has published data on what that impurity does in the body. Treat it as a manufacturer finding, not a regulator’s determination — but treat it as a real open question.

What about pills, drops and under-the-tongue tablets?

FDA has approved tirzepatide only for injection under the skin [17].

Several platforms sold oral versions anyway: an orally dissolving tablet, products marketed as “Tirzepatide Drops,” and sublingual tablets. Eli Lilly’s court filings call these untested knockoffs, and its own medical information page states that no regulator has evaluated the safety or effectiveness of pill or oral versions of tirzepatide [17]. The Connecticut Attorney General told clinics in 2025 that oral GLP-1 products from compounding pharmacies have not been shown to deliver safe or effective doses [18].

Peptides are poorly absorbed by mouth without a specialized absorption enhancer, which is a real pharmacological obstacle, not a marketing quibble. If a seller offers oral tirzepatide, that is a signal about the seller.

One point of confusion worth heading off: Lilly does sell an approved oral GLP-1, Foundayo (orforglipron). That is a different molecule — a small molecule, not a peptide — and it is not oral tirzepatide.

Is compounded tirzepatide safe?

Nobody can answer that as a category, because there is no category-wide oversight. What exists is a pattern of specific findings.

As of May 31, 2026, FDA had received more than 730 adverse event reports associated with compounded tirzepatide, alongside 990 for compounded semaglutide, a combined total above 1,700 [19]. FDA cautions the real number is likely higher, because state-licensed pharmacies that are not outsourcing facilities are not required to report adverse events. Many of the reported events resemble those seen with the approved products.

FDA has also documented problems specific to the compounded supply chain:

• Fraudulent labels. Some compounded semaglutide and tirzepatide vials carry the name of a pharmacy that does not exist, or a real pharmacy that did not make the product [3]. That breaks the most obvious verification step a patient has.
• Sterility failures. A 503B facility recalled a tirzepatide injection lot in October 2025 for lack of sterility assurance [11]. A January 2026 warning letter to another pharmacy described tirzepatide lots testing at 86.8 and 89.1 percent of label strength, and a tirzepatide-glycine-methylcobalamin lot that failed sterility testing and was distributed anyway [20].
• Unlicensed suppliers. In the JAMA Health Forum study, four of 23 analyzed supplying compounding facilities were not licensed to perform sterile compounding at all [14].

None of that means every compounded product is dangerous. It means quality rests entirely on the individual pharmacy, and you have to check.

How can I tell whether what I’m being offered is lawful?

Ask these questions, in writing, before you pay.

1. Which pharmacy will fill this, by legal name and state? Then look it up on that state’s board of pharmacy license database.
2. Does that pharmacy hold a sterile compounding license? Roughly one in five analyzed suppliers in the 2026 study did not [14].
3. Is it a 503A pharmacy or an FDA-registered 503B outsourcing facility? If 503B, check FDA’s registered outsourcing facilities list and its compounding inspections and recalls page [21].
4. Is the active ingredient tirzepatide base, or a salt form? FDA has said it is not aware of a lawful basis for using salt forms in compounding, and no published trial has tested a tirzepatide salt in humans [3].
5. Can I see a lot-matched certificate of analysis? Dated within the last six months, with potency, sterility and endotoxin results.
6. What is the documented clinical reason the approved product will not work for me? If the prescriber cannot answer this clearly, the 503A pathway is not really being used.
7. Is the price the medication, or the membership, or both? Many quoted figures are one and not the other.

A provider who answers all seven readily is operating differently from one who deflects.

The bottom line

Compounded tirzepatide is not banned. It is also not the freely available, deeply discounted product it was in 2024. The shortage exception that built the market is gone, courts have upheld its removal, the 503B bulk route is likely closing permanently, and what remains is a narrow patient-specific lane that requires a documented clinical reason.

Meanwhile the price argument that drove people to compounded product has weakened considerably. Cash-pay branded Zepbound through the manufacturer’s own channel now runs $299 to $449 a month depending on dose (verified 2026-09-14), which is inside or near the range many compounded programs charge once a membership fee is added. That is a range by dose, not a single price, and the $449 top tier is a Self Pay Journey Program price conditioned on refilling within 45 days of the previous delivery; outside that window Lilly’s own announcement lists $599 at 7.5 mg rising to $1,049 at 15 mg.

If you are currently using compounded tirzepatide, the useful next step is not to stop on your own. It is to ask your prescriber which pathway they are using and why, and to price the branded route alongside it. Talk to a healthcare provider about which option fits your situation.

Sources

1. Authentic Zepbound (tirzepatide) Shipped to You — LillyDirect
2. Outsourcing Facilities Association v. FDA, No. 25-10600 (5th Cir. Aug. 27, 2026)
3. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
4. An Open Letter From Eli Lilly and Company Regarding Certain Practices Related to Mounjaro and Zepbound
5. Compounding when Drugs are on FDA’s Drug Shortages List
6. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
7. Eli Lilly sues companies selling alternative versions of its weight loss drug — NPR
8. Court sides with FDA in tirzepatide shortage fight: 5 notes — Becker’s
9. Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list — STAT
10. Fifth Circuit Upholds FDA on GLP-1 Shortage Decisions — Clark Hill
11. FDA warning letter to ProRx LLC, MARCS-CMS 723704 (April 7, 2026)
12. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
13. List of Bulk Drug Substances … Extension of Comment Period, 91 FR 38719
14. DiStefano MJ et al., Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand, JAMA Health Forum 2026;7(7):e262207
15. Compounded GLP-1s Still Widespread Despite Shortage Fix — Medscape
16. Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks — Reuters
17. What are the health risks of using compounded tirzepatide? — Lilly Medical Information
18. Connecticut Attorney General letter to weight loss clinics and spas (May 21, 2025)
19. FDA warns on compounded GLP-1s amid 1,700-plus safety reports — Becker’s
20. FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs — The FDA Group
21. Compounding: Inspections, Recalls, and other Actions — FDA